Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung

Federico González-Aragoneses, Nicolás Moreno-Mata, María Cebollero-Presmanes, Mariano García-Yuste, Miguel Ángel Cañizares-Carretero, Laureano Molins-López-Rodó, Santiago Quevedo-Losada, Juan Torres-Lanzas, Emilio Álvarez-Fernández, Ana Almaraz, María F. Muñoz, William D. Travis, Richard J Battafarano, Pierre Fuentes

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung. METHODS. A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I. RESULTS. In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma). Eighty-six tumors showed a presence of SY+ (27%). Univariate analysis showed lower survival rates at 5 years for those patients older than 70 years of age compared with those patients younger than 70 years of age (60.35% vs 70.57%; P = .007) and for those patients with SY+ compared with those with SY- (52.48% vs 72.68%; P = .0017). Patients with SY+ tumors showed a higher rate of recurrence than patients with SY- tumors (50% vs 33.6%; P = .008). Multivariate analysis showed that those patients greater that 70 years of age (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.14-2.65) and the presence of SY (HR, 2.15; 95% CI, 1.40-3.30) were significant independent prognostic factors associated with a poor outcome. CONCLUSIONS. Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.

Original languageEnglish (US)
Pages (from-to)1776-1781
Number of pages6
JournalCancer
Volume110
Issue number8
DOIs
StatePublished - Oct 15 2007
Externally publishedYes

Fingerprint

Synaptophysin
Squamous Cell Carcinoma
Adenocarcinoma
Survival Rate
Adenocarcinoma of lung
Confidence Intervals
Recurrence
Neoplasms
Multivariate Analysis
Retrospective Studies
Staining and Labeling

Keywords

  • Immunohistochemistry
  • Neuroendocrine differentiation
  • Squamous carcinoma and adenocarcinoma of the lung
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

González-Aragoneses, F., Moreno-Mata, N., Cebollero-Presmanes, M., García-Yuste, M., Cañizares-Carretero, M. Á., Molins-López-Rodó, L., ... Fuentes, P. (2007). Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer, 110(8), 1776-1781. https://doi.org/10.1002/cncr.22985

Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. / González-Aragoneses, Federico; Moreno-Mata, Nicolás; Cebollero-Presmanes, María; García-Yuste, Mariano; Cañizares-Carretero, Miguel Ángel; Molins-López-Rodó, Laureano; Quevedo-Losada, Santiago; Torres-Lanzas, Juan; Álvarez-Fernández, Emilio; Almaraz, Ana; Muñoz, María F.; Travis, William D.; Battafarano, Richard J; Fuentes, Pierre.

In: Cancer, Vol. 110, No. 8, 15.10.2007, p. 1776-1781.

Research output: Contribution to journalArticle

González-Aragoneses, F, Moreno-Mata, N, Cebollero-Presmanes, M, García-Yuste, M, Cañizares-Carretero, MÁ, Molins-López-Rodó, L, Quevedo-Losada, S, Torres-Lanzas, J, Álvarez-Fernández, E, Almaraz, A, Muñoz, MF, Travis, WD, Battafarano, RJ & Fuentes, P 2007, 'Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung', Cancer, vol. 110, no. 8, pp. 1776-1781. https://doi.org/10.1002/cncr.22985
González-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, García-Yuste M, Cañizares-Carretero MÁ, Molins-López-Rodó L et al. Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer. 2007 Oct 15;110(8):1776-1781. https://doi.org/10.1002/cncr.22985
González-Aragoneses, Federico ; Moreno-Mata, Nicolás ; Cebollero-Presmanes, María ; García-Yuste, Mariano ; Cañizares-Carretero, Miguel Ángel ; Molins-López-Rodó, Laureano ; Quevedo-Losada, Santiago ; Torres-Lanzas, Juan ; Álvarez-Fernández, Emilio ; Almaraz, Ana ; Muñoz, María F. ; Travis, William D. ; Battafarano, Richard J ; Fuentes, Pierre. / Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. In: Cancer. 2007 ; Vol. 110, No. 8. pp. 1776-1781.
@article{bea2025ca26c4bfa9b9f34e84cd92d72,
title = "Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung",
abstract = "BACKGROUND. The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung. METHODS. A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I. RESULTS. In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma). Eighty-six tumors showed a presence of SY+ (27{\%}). Univariate analysis showed lower survival rates at 5 years for those patients older than 70 years of age compared with those patients younger than 70 years of age (60.35{\%} vs 70.57{\%}; P = .007) and for those patients with SY+ compared with those with SY- (52.48{\%} vs 72.68{\%}; P = .0017). Patients with SY+ tumors showed a higher rate of recurrence than patients with SY- tumors (50{\%} vs 33.6{\%}; P = .008). Multivariate analysis showed that those patients greater that 70 years of age (hazard ratio [HR], 1.74; 95{\%} confidence interval [CI], 1.14-2.65) and the presence of SY (HR, 2.15; 95{\%} CI, 1.40-3.30) were significant independent prognostic factors associated with a poor outcome. CONCLUSIONS. Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.",
keywords = "Immunohistochemistry, Neuroendocrine differentiation, Squamous carcinoma and adenocarcinoma of the lung, Survival",
author = "Federico Gonz{\'a}lez-Aragoneses and Nicol{\'a}s Moreno-Mata and Mar{\'i}a Cebollero-Presmanes and Mariano Garc{\'i}a-Yuste and Ca{\~n}izares-Carretero, {Miguel {\'A}ngel} and Laureano Molins-L{\'o}pez-Rod{\'o} and Santiago Quevedo-Losada and Juan Torres-Lanzas and Emilio {\'A}lvarez-Fern{\'a}ndez and Ana Almaraz and Mu{\~n}oz, {Mar{\'i}a F.} and Travis, {William D.} and Battafarano, {Richard J} and Pierre Fuentes",
year = "2007",
month = "10",
day = "15",
doi = "10.1002/cncr.22985",
language = "English (US)",
volume = "110",
pages = "1776--1781",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung

AU - González-Aragoneses, Federico

AU - Moreno-Mata, Nicolás

AU - Cebollero-Presmanes, María

AU - García-Yuste, Mariano

AU - Cañizares-Carretero, Miguel Ángel

AU - Molins-López-Rodó, Laureano

AU - Quevedo-Losada, Santiago

AU - Torres-Lanzas, Juan

AU - Álvarez-Fernández, Emilio

AU - Almaraz, Ana

AU - Muñoz, María F.

AU - Travis, William D.

AU - Battafarano, Richard J

AU - Fuentes, Pierre

PY - 2007/10/15

Y1 - 2007/10/15

N2 - BACKGROUND. The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung. METHODS. A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I. RESULTS. In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma). Eighty-six tumors showed a presence of SY+ (27%). Univariate analysis showed lower survival rates at 5 years for those patients older than 70 years of age compared with those patients younger than 70 years of age (60.35% vs 70.57%; P = .007) and for those patients with SY+ compared with those with SY- (52.48% vs 72.68%; P = .0017). Patients with SY+ tumors showed a higher rate of recurrence than patients with SY- tumors (50% vs 33.6%; P = .008). Multivariate analysis showed that those patients greater that 70 years of age (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.14-2.65) and the presence of SY (HR, 2.15; 95% CI, 1.40-3.30) were significant independent prognostic factors associated with a poor outcome. CONCLUSIONS. Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.

AB - BACKGROUND. The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung. METHODS. A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I. RESULTS. In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma). Eighty-six tumors showed a presence of SY+ (27%). Univariate analysis showed lower survival rates at 5 years for those patients older than 70 years of age compared with those patients younger than 70 years of age (60.35% vs 70.57%; P = .007) and for those patients with SY+ compared with those with SY- (52.48% vs 72.68%; P = .0017). Patients with SY+ tumors showed a higher rate of recurrence than patients with SY- tumors (50% vs 33.6%; P = .008). Multivariate analysis showed that those patients greater that 70 years of age (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.14-2.65) and the presence of SY (HR, 2.15; 95% CI, 1.40-3.30) were significant independent prognostic factors associated with a poor outcome. CONCLUSIONS. Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.

KW - Immunohistochemistry

KW - Neuroendocrine differentiation

KW - Squamous carcinoma and adenocarcinoma of the lung

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=35048862036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048862036&partnerID=8YFLogxK

U2 - 10.1002/cncr.22985

DO - 10.1002/cncr.22985

M3 - Article

C2 - 17724707

AN - SCOPUS:35048862036

VL - 110

SP - 1776

EP - 1781

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -